{"podcast":{"title":"In the Interim...","slug":"in-the-interim-7211889","podcast_index_feed_id":7211889,"rss_url":"https://feeds.transistor.fm/in-the-interim","website_url":"https://berryconsultants.com","image_url":"https://img.transistorcdn.com/4kEBoJ9pC_kLNSr6AX2uD_qdxx8BJ7dMddtvubROpQ0/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jM2M0/ZDE2YzA1N2FhNjkx/NDk1NDczNjYzM2E5/NjlmYS5wbmc.jpg","author":"Berry","episode_count":77,"summary":"A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.","last_synced_at":"2026-09-08T00:17:11.625653+00:00","page_url":"https://stenobird.com/podcast/in-the-interim-7211889"},"episode":{"title":"Adaptive Design Actions Matrix","slug":"adaptive-design-actions-matrix","published_at":"2026-07-27T11:00:00+00:00","page_url":"https://stenobird.com/podcast/in-the-interim-7211889/adaptive-design-actions-matrix","show_page_url":"https://stenobird.com/podcast/in-the-interim-7211889","url":"https://share.transistor.fm/s/33c72055","audio_url":"https://media.transistor.fm/33c72055/7cb72120.mp3","summary":"In this episode of \"In the Interim…\", Dr. Scott Berry challenges the widely held belief that any interim look at trial data obligates an alpha adjustment. By constructing a two-by-two matrix: interim data (positive/negative) and adaptive action (increase/decrease sample size), Scott demonstrates that the need for statistical correction depends on precisely what actions are prespecified. He emphasizes that the need for adjustment depends on the action and the data. Technical scenarios examined include group sequential designs, “promising zone” sample size re-estimation (citing the formal results of Mehta and Pocock), and response adaptive randomization. Scott stresses that clear prespecification is required for Type I error control and regulatory compliance. He critiques common missteps, such as unnecessary allocation of alpha to futility boundaries when superiority is not planned, and reiterates that it is the adaptive action, and not mere data review, that determines the statistical impact of interim analyses. Key Highlights Dissects alpha adjustment myths and their historical roots. Details two-by-two matrix: interim data direction and adaptive action. Explores group sequential, futility, promising zone, and response adaptive examples. Clarifies when Type I error is truly affected—action and data matter. Stresses prespecification’s role in trial validity and regulatory acceptance. Identifies pitfalls in common trial design practices. For more, visit us at https://www.berryconsultants.com/","meta_description":"In this episode of \"In the Interim…\", Dr. Scott Berry challenges the widely held belief that any interim look at trial data obligates an alpha adjustment.…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1843,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/in-the-interim-7211889/episodes/adaptive-design-actions-matrix/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/in-the-interim-7211889/adaptive-design-actions-matrix.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}